Understanding Immune Therapy Side Effects and Biomarkers
Part of Immune system & allergy clinical trials.
This study looks for biological signals (biomarkers) that might predict who will experience side effects from immune checkpoint inhibitor cancer treatments. By understanding these signals early, doctors may be able to better manage or prevent serious immune-related complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 years or older
- Able to care for yourself with some help (Karnofsky score above 60)
- Planning to start immune checkpoint inhibitor therapy for the first time
- Expected to live at least 6 months
- No prior immune checkpoint inhibitor treatment
- Able to provide blood or tissue samples during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at side effects from immune checkpoint inhibitors in people with solid tumors. It aims to understand why side effects happen and who might be at risk, so doctors can better manage them.
This study looks at patients who had side effects from cancer immunotherapy (checkpoint inhibitors). The goal is to understand those side effects and whether it is safe to restart immunotherapy after they resolve.
This trial aims to improve how doctors spot and track side effects from immunotherapy. If you are on or have had immunotherapy, your experience can help build a better system for monitoring these treatments.
This study tries to predict who is more likely to get serious side effects from immune checkpoint medicines used for solid tumors. You may help researchers by answering questionnaires before treatment and during follow-up, and by possibly storing sample specimens.
This study watches immune system markers to see if they can predict which patients will respond well to immunotherapy and who might have side effects. If you have cancer and are starting immunotherapy, this trial may help guide future treatment decisions.
This study looks at how side effects happen in people receiving immune checkpoint inhibitor immunotherapy for solid cancers. It uses multiple types of tests to better understand these toxicities and may help improve safety and care in the future.
Hear when a new Immune-Related Adverse Events trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.